Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study page now displays a 403 Forbidden error rather than the study details, indicating access is blocked or restricted. This prevents viewing the trial information while the underlying data remains unchanged.SummaryDifference20%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, signaling a new site build or update for the study details page.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page’s revision label was updated to v3.6.5, indicating a new maintenance release of the study page. No study details or content appear to have changed as part of this update.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This represents a minor update to the page's revision history rather than changes to the study details or user-facing content.SummaryDifference0.0%

- Check88 days agoChange DetectedThe page revision tag was updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a small housekeeping update to the page's metadata rather than a change to the study details.SummaryDifference0.0%

- Check95 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a minor maintenance update to the page version without altering study details.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.